Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates

Thrombosis and Haemostasis

Volumn 80, Issue 3, 1998, Pages 399-402

  Köhler, Michael ^a   Hellstern, Peter ^b   Lechler, Eckhard ^b   Überfuhr, Peter ^b   Müller Berghaus, Gert ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 9 CONCENTRATE; PROTHROMBIN COMPLEX;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; GERMANY; HEPATITIS B; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS; VIRUS TRANSMISSION;

EID: 0031754792     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615219     Document Type: Article

References (38)

1. Didisheim P, Loeb J, Blatrix C, Soulier JP. Preparation of a human plasma fraction rich in prothrombin, proconvertin, stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med 1959; 53: 322-30.
2. Surgenor DM, Melin M, Steele BB, Wheaton L, Penell RB. Preparation of barium sulfate eluate of plasma for physiological studies in humans. Vox Sang 1959; 4: 71-2.
3. Kasper, CK. Thromboembolic complications-Task Force report. Thrombos Diathes Haemorrh 1975; 33: 677-44.
4. Menache D. Report of the Task Force on the clinical use of factor IX concentrates. Thromb Haemost 1976; 35: 748-50.
5. Menache D, Roberts HR. Summary report and recommendations of the Task Force members and consultants. Thromb Diathes Haemorrh 1976; 33: 645-7.
6. Lusher J. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 (Suppl 3): 3-5.
7. Lusher J. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol 1993; 30 (Suppl 1): 36-40.
8. Barrowcliffe TW. Viral inactivation vs. biological activity. Dev Biol Stand 1993; 81: 125-35.
9. Arzneimittelkommission der deutschen Ärzteschaft. Beriplex HS 250, Beriplex HS 500. Paul-Ehrlich-Institut (PEI). Deutsches Ärzteblatt 1994; 91: 2056.
10. Arzneimittelkommission der deutschen Ärzteschaft. PPSB (Prothrombinkomplex) human 250,-500 bzw. PPSB-Serapharm 250, -500. Paul-Ehrlich-institut (PEI). Abwehr von Arzneimittelrisiken. Stufe II. Deutsches Ärzteblatt 1994; 91: 1884.
11. Köhler M, Hellstern P, Müller-Berghaus G, Lechler E. Thromboembolische Komplikationen durch Prothrombinkomplex-Präparate. Deutsches Ärzteblatt 1995; 92: 1863-5.
12. Chavin SI, Siegel DM, Rocco TM, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 245-9.
13. Aledort LM. Factor IX and thrombosis. Scand J Haematol 1977; 30 (Suppl): 40-2.
14. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thrombos Haemost 1989; 15: 58-88.
15. Hirsh J, Prins MH, Samama M. Approach to the thrombophilic patient. In: Thrombosis and Haemostasis: Basic principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman E, eds. Philadelphia: J. B. Lippincott 1994; 1543-61.
16. Pinskv DJ. The vascular biology of heart and lung preservation for trans-plantation. Thrombos Haemost 1995; 74: 58-65.
17. Mannucci PM, Franci F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet 1976; i: 542-5.
18. Prowse CW, Cash JD. The use of factor IX concentrates in man: A 9-year experience .Br J Haematol 1981; 47: 91-104.
19. Trobisch H, Hantland P. PPSB. In: Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer, eds., Köln: Deutscher Ärzte-Verlag 1995; 81-95.
20. Diffang C, Saldeen T. Effects of Trasylol on fibrin deposition and elimination in the lung of rats with intravascular coagulation induced by thrombin or thromboplastin. Thromb Res 1974; 5: 263-76.
21. Samama CM, Mazoyer E, Bruneval P, Ciostek P, Bonnin P, Bonneau M, Roussi J, Baillart O, Pignaud G, Viars P, Caen JP, Drouet LO. Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb Haemost 1994; 71: 663-9.
22. Bohrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 1990; 4: 222-5.
23. Saffitz JE, Stahl DJ, Sundt TM, Wareing TH, Kouchoukos NT. Disseminated intravascular coagulation after administration of Aprotinin in combination with deep hypothermie circulatory arrest. Am J Cardiol 1993; 72: 1080-2.
24. Sundt TM, Kouchoukos NT, Saffitz JE, Murphy S, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-24.
25. Umbrain V, Christiaens F, Camu F. Intraoperative coronary thrombosis: Can aprotinin and protamine be incriminated? J Cardiothorac Vase Anesth 1994; 8: 198-201.
26. van der Meer J, Hillege HL, Ascop CAPL, Dunselman JM, Mulder BJM, van Ommen GVA, Pfisterer M, van Gilst WH, Lie KI. Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996; 75: 1-3.
27. Ray MJ, Marsh NA, Mengerson K. A brief review of studies evaluating the adverse effects of aprotinin therapy in aortocoronary bypass surgery [Letter]. Thromb Haemost 1997; 77: 1038-40.
28. Bohrer H. Personal communication. September 27, 1997.
29. Seligsohn U, Kasper CK, Osterud B, Rapaport CI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-37.
30. White GC, Roberts HR, Kingdon HS, Lundblud RL. Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-70.
31. Gray E, Tubbs J, Thomas S, Oales A, Boisclair M, Kemball-Cook G, Barrowcliffe TW. Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-9.
32. Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EGD, Lowe GDO, Rumley A, Ludlam CA. High purity factor IX and prothrombin complex concentrate (PCC): Pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996; 76: 23-8.
33. Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann, KG. The coagulant active phospholipid is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401-7.
34. Magner A, Aronson D. Toxicity of factor IX concentrates in mice. Develop Biol Standard 1979; 44: 185-8.
35. Köhler M, Heiden M, Harbauer G, Miyashita C, Mörsdorf S, Braun B, Ernert P, Wenzel E, Rose S, Pindur G. Comparison of different prothrombin complex concentrates: In vitro and in vivo studies. Thromb Res 1990; 60: 63-70.
36. Heinemann H, Schramm W, Hoffmann P. Lierz P. Multiorganversagen nach Gabe von PPSB beim isolierten Faktor-VII-Mangel. Anästhesiol Intensivmed 1993; 34: 130-4.
37. Hellstern P, Köhler M. Prothrombin complex concentrates (PCC) and thromboembolic complications [Abstract]. Ann Haematol 1995; 70 (suppl 1): A88.
38. Hellstem P, Beeck H, Fellhauer A, Fischer A, Faller-Stöckl B. Factor VII and activated factor VII content of prothrombin complex concentrates. Vox Sang 1997; 73: 155-61.